CN108348552A - 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 - Google Patents

通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 Download PDF

Info

Publication number
CN108348552A
CN108348552A CN201680064239.2A CN201680064239A CN108348552A CN 108348552 A CN108348552 A CN 108348552A CN 201680064239 A CN201680064239 A CN 201680064239A CN 108348552 A CN108348552 A CN 108348552A
Authority
CN
China
Prior art keywords
allogeneic
cell
homogeneous variant
cells
cell group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680064239.2A
Other languages
English (en)
Chinese (zh)
Inventor
冈瑟·科伊内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN108348552A publication Critical patent/CN108348552A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680064239.2A 2015-09-10 2016-09-09 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 Pending CN108348552A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
CN108348552A true CN108348552A (zh) 2018-07-31

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680064239.2A Pending CN108348552A (zh) 2015-09-10 2016-09-09 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法

Country Status (14)

Country Link
US (1) US20190381098A1 (https=)
EP (1) EP3347028A1 (https=)
JP (1) JP6947720B2 (https=)
KR (1) KR20180048992A (https=)
CN (1) CN108348552A (https=)
AU (1) AU2016320877A1 (https=)
CA (1) CA2997757A1 (https=)
HK (1) HK1257882A1 (https=)
IL (1) IL257929B2 (https=)
MX (1) MX395106B (https=)
RU (1) RU2743381C2 (https=)
TW (1) TWI759270B (https=)
WO (1) WO2017044678A1 (https=)
ZA (1) ZA201801656B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632A (zh) * 2021-09-29 2022-01-04 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1314916A (zh) * 1998-07-31 2001-09-26 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
CN101580538A (zh) * 2003-11-05 2009-11-18 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
CN102165057A (zh) * 2008-05-16 2011-08-24 法国血液机构 用于主动或过继性细胞疗法的类浆细胞树突细胞系
CN102271702A (zh) * 2008-10-30 2011-12-07 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
WO2013106834A2 (en) * 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1314916A (zh) * 1998-07-31 2001-09-26 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
CN101580538A (zh) * 2003-11-05 2009-11-18 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
CN102165057A (zh) * 2008-05-16 2011-08-24 法国血液机构 用于主动或过继性细胞疗法的类浆细胞树突细胞系
CN102271702A (zh) * 2008-10-30 2011-12-07 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
WO2013106834A2 (en) * 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A.G. CHAPUIS ET AL.: "Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients", 《SCI TRANSL MED.》 *
AKIHIRO TSUBOI ET AL.: "Wilms Tumor Gene WT1 Peptide–Based Immunotherapy Induced a Minimal Response in a Patient with Advanced Therapy-Resistant Multiple Myeloma", 《INTERNATIONAL JOURNAL OF HEMATOLOGY》 *
BRITTA EIZ-VESPER ET AL.: "Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry", 《FRONTIERS IN IMMUNOLOGY》 *
ELEANOR M. TYLER ET AL.: "WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusions", 《BLOOD》 *
G. KOEHNE ET AL.: "Wilms’ tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches", 《INTERNATIONAL MYELOMA WORKSHOP》 *
O’REILLY ET AL.: "T-cell Depleted Allogeneic Hematopoietic Cell Transplants As A Platform For Adoptive Therapy With Leukemia Selective Or Virus-Specific T-cells", 《BONE MARROW TRANSPLANTATION》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632A (zh) * 2021-09-29 2022-01-04 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Also Published As

Publication number Publication date
TWI759270B (zh) 2022-04-01
IL257929B1 (en) 2024-02-01
WO2017044678A1 (en) 2017-03-16
HK1257882A1 (zh) 2019-11-01
IL257929B2 (en) 2024-06-01
EP3347028A1 (en) 2018-07-18
US20190381098A1 (en) 2019-12-19
ZA201801656B (en) 2022-12-21
TW201714619A (zh) 2017-05-01
RU2018112526A (ru) 2019-10-10
KR20180048992A (ko) 2018-05-10
JP2018530534A (ja) 2018-10-18
RU2743381C2 (ru) 2021-02-17
MX395106B (es) 2025-03-21
IL257929A (en) 2018-05-31
JP6947720B2 (ja) 2021-10-13
CA2997757A1 (en) 2017-03-16
AU2016320877A1 (en) 2018-04-19
MX2018002816A (es) 2018-06-08
RU2018112526A3 (https=) 2020-01-31

Similar Documents

Publication Publication Date Title
US20230002730A1 (en) Improved targeted t-cell therapy
KR102509006B1 (ko) 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체
US20230172986A1 (en) Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors
TWI759270B (zh) 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法
US20210213066A1 (en) Improved cell therapy compositions for hematopoietic stem cell transplant patients
KR20220066165A (ko) 조절 t 세포를 포함하는 조성물 및 그의 제조 및 사용 방법
BRPI0815578B1 (pt) peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
EP3294304B1 (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
JP7808377B2 (ja) 乳がんおよび卵巣がんワクチン
CA3126066A1 (en) Ex vivo activated t-lymphocytic compositions and methods of using the same
JP2022512538A (ja) Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
JP2020506943A (ja) 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
Tanaka et al. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome
EP3765602A1 (en) Methods of selecting t cell line for adoptive cellular therapy
Amoozgar et al. Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells
Ferulli et al. Generation of donor-derived Wilms tumor antigen 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study
US20160375060A1 (en) Methods of Treating Glioblastoma Multiforme by T Cell Therapy
HK40050731A (en) Improved targeted t-cell therapy
US11925663B2 (en) Methods of managing tumor flare in adoptive immunotherapy
Lichtenegger et al. ltmann, T
HK1244697B (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination